Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer



Status:Completed
Conditions:Cervical Cancer, Cervical Cancer, Cancer, Women's Studies
Therapuetic Areas:Oncology, Reproductive
Healthy:No
Age Range:18 - Any
Updated:5/3/2014
Start Date:June 2012
End Date:June 2014
Contact:Oguz Akin, MD
Phone:212-639-3458

Use our guide to learn which trials are right for you!

This study is to assess how patients respond to their treatment for cervical cancer. This
research does not involve a specific treatment for the cancer that will be recommended by
the doctor and may include radiation therapy and/or chemotherapy. This is a separate
research imaging study designed to assess how patients respond to their treatment for
cervical cancer.


Inclusion Criteria:

- Biopsy-documented, newly-diagnosed primary cervical cancer of all histopathology
types.

- Clinically visible gross lesion (International Federation of Gynecology and
Obstetrics (FIGO) stage IB1 and above).

- Treatment (chemoradiation), DCE-MRI and 18F-FMISO PET studies will be at MSKCC.

- Patients must be an adult female 18 years of age or older.

Exclusion Criteria:

- Patients who because of general medical or psychiatric condition, or physiologic
status cannot give an informed consent.

- Patients who received prior radiation treatment to pelvis.

- Patients with contraindications to DCE-MRI (non-compatible cardiac pacemakers or
intracranial vascular clips, allergy to Gadolinium, end-stage renal disease) and/or
18F-FMISO PET.

- Patients who do not fulfill the screening criteria for safe DCE-MRI or 18F-FMISO PET
as per the Department of Radiology guidelines.

- Pregnant patients; and or patients who are breast-feeding their babies.
We found this trial at
1
site
1275 York Avenue
New York, New York 10065
212-639-2000
Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private...
?
mi
from
New York, NY
Click here to add this to my saved trials